Nanosonics Ltd (Nanosonics) medical technology company that develops, manufactures, and sells automated infection prevention solutions for reusable medical devices. Its main product is the trophon platform, which provides automated high-level disinfection of ultrasound probes using a sonically activated hydrogen peroxide mist. The company's latest trophon series product, trophon3, offers a four-minute cycle, compared with seven minutes for earlier trophon models, and includes enhanced digital traceability and is compatible with more than 1,400 ultrasound probes from more than 30 manufacturers. Nanosonics also provides trophon2 Plus, a software upgrade for existing trophon2 systems, and Nanosonics Connect, a cloud-based solution that records, monitors, and manages reprocessing data. The company’s digital tools can integrate with hospital imaging systems through DICOM and support mobile record keeping across clinical departments. Nanosonics' further product portfolio includes the CORIS System, an automated technology for cleaning narrow and difficult-to-brush channels inside flexible endoscopes. The CORIS System uses PULSS technology and the proprietary CORIS QUANTUM cleaning agent to create controlled physical friction that removes soil and biofilm.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Nanosonics undertook R&D initiatives that supported the development of the CORIS system for automated flexible endoscope cleaning, Nanosonics connect digital traceability, and enhancements to the trophon platform, including trophon3 and trophon2 Plus. The CORIS system advanced through controlled market releases, real-world hospital testing, regulatory clearances in Australia, the EU, the UK, and the US, and preparation for broader commercialization in FY2027. The R&D unit of the company includes manufacturing and R&D laboratory and office facilities at Macquarie Park, Australia. The company has a portfolio that includes more than 340 patent assets issued or pending globally, covering ultrasound reprocessing, endoscope cleaning, digital solutions, and related applications. In FY2026, the company spent AUD29 million on its R&D, whch is as a percentage of its revenue stood at 14.3%.